ArticleInternational journal of molecular sciences2026
Ginsenoside Rh2 Attenuates Intervertebral Disc Degeneration by Modulating the PI3K/AKT Signaling Pathway to Suppress Apoptosis.
Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Intervertebral disc degeneration (IVDD) is a major cause of chronic low back pain and imposes a substantial socioeconomic burden. Ginsenoside Rh2 (Gin-Rh2), a bioactive ginseng compound with antioxidant properties, may have therapeutic potential in IVDD, but its effects and underlying mechanisms remain unclear. Here, we evaluated Gin-Rh2 in cellular and rat models of IVDD. In vitro, Gin-Rh2 attenuated interleukin-1β (IL-1β)-induced nucleus pulposus cell apoptosis, reduced matrix metalloproteinase-3 (MMP3) expression, and increased aggrecan and type II collagen production. Network pharmacology and molecular docking implicated the phosphoinositide 3-kinase/protein kinase B (PI3K/AKT) pathway as a potential target. Mechanistic experiments further indicated that inhibition of PI3K/AKT signaling contributed to the protective effects of Gin-Rh2, whereas pharmacological activation of this pathway partially attenuated these effects. In vivo, Gin-Rh2 attenuated puncture-induced disc degeneration. Collectively, these findings suggest that Gin-Rh2 protects nucleus pulposus cells and attenuates experimental IVDD, supporting its further investigation as a potential therapeutic candidate.
Indexed as
Identifiers
42794657What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.